Ariad Pharmaceuticals reported that it has entered a nonexclusive license agreement with Icon Medical to develop drug-eluting stents that deliver Ariad's mTOR inhibitor, deforolimus, to prevent restenosis of injured vessels following angioplasty /stenting.

Deals

Name: Relias Media
Price range: $

January 2, 2015

Reprints

Recognizing, Managing, and Reporting Pediatric Sexual Abuse and Assault
Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations
Indiana Appellate Court Allows Case to Proceed Against Doctor Accused of Improperly Accessing Patients’ Medical Records
Malpractice Insurance Rates Increasing After Stable Period
Clinical Decision Software Highly Effective in OR